ETO AGORAStop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024, Section 103. "Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs"
Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024, Section 103. "Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs"
Develops a joint strategy to accelerate research, development, and deployment of AI and other technologies to detect illicit synthetic drugs. Requires report submission to specified congressional committees within two years.
Require the Director of the Office of Science and Technology Policy and the Director of the Office of National Drug Control Policy to develop a strategy for accelerating the research, development, and deployment of advanced inspection technologies, including AI and quantum computing, to detect illicit synthetic drugs.
Mandate coordination with multiple agencies, including the National Science Foundation and the National Institute of Standards and Technology.
Instruct submission of a report on the strategy to specified congressional committees within two years of the Act's enactment.
Key facts
🏛️ This document was proposed and/or enacted by the United States Congress but is now defunct.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the government, rather than the private sector.
📜 This document's name is Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024.
AGORA also tracks this document under the name Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024, Section 103. "Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs". It is part of Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024.
Some AGORA documents are "split off" from longer documents that mix AI
and non-AI content, such as omnibus authorization or appropriations laws
in the United States Congress. Read more >>
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that facilitate, require, set conditions on, or otherwise address the convening of different stakeholders in AI systems - for example, to share feedback or to participate in its development or deployment.
This tag applies to documents that require, authorize, encourage, or allocate resources for AI-related studies, reports, or plans to be prepared by or for the government.
This tag applies to documents that authorize, plan for, allocate resources for, define eligibility for, create or revise procedures for, or otherwise manage government support for AI-related activities to be carried out inside or outside of government. "Support" includes any thing of value, including but not limited to money.
This tag applies to documents that address government support for AI-related research and development (R&D). R&D includes activities meant to create or improve technologies, products, and scientific knowledge.
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
SEC. 103. Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs.
(a) Defined term.—In this section, the term “appropriate congressional committees” means—
(1) the Committee on Commerce, Science, and Transportation of the Senate;
(2) the Committee on Homeland Security and Governmental Affairs of the Senate;
(3) the Committee on Finance of the Senate;
(4) the Committee on the Judiciary of the Senate;
(5) the Committee on Energy and Commerce of the House of Representatives;
(6) the Committee on Homeland Security of the House of Representatives;
(7) the Committee on Financial Services of the House of Representatives; and
(8) the Committee on the Judiciary of the House of Representatives.
Defines "appropriate congressional committees" for strategy development on advanced drug detection technologies.
Defines "appropriate congressional committees" for strategy development on advanced drug detection technologies.
(b) In general.—The Director of the Office of Science and Technology Policy and the Director of the Office of National Drug Control Policy, in consultation and coordination with the Director of the National Science Foundation, the Secretary of Commerce (acting through the Director of the National Institute of Standards and Technology), the Secretary of Energy, the Secretary of Homeland Security, the Administrator of the Transportation Security Administration, and the Attorney General, shall—
(1) develop a joint strategy to accelerate research and development and deployment of non-intrusive, advanced inspection technologies and other advanced inspection technologies to detect illicit synthetic drugs, such as artificial intelligence and quantum hybrid computing and integration of multiple data sources; and
(2) not later than 2 years after the date of the enactment of this Act, submit a report on such strategy to the appropriate congressional committees.
Develops a strategy for advanced drug detection technologies, and submits a report to Congress within two years.
Develops a strategy for advanced drug detection technologies, and submits a report to Congress within two years.